Abstract
The majority of Hodgkin lymphoma patients are now cured with conventional first-line therapy; however, 10-15% of early-stage disease and less than 30% of advanced-stage patients are refractory(rare) or relapsed. Salvage second-line therapy combined with high-dose therapy and autologous stem-cell transplantation can cure 40-50% of patients. Recently novel agents (Brentuximab Vedotin and Immune Checkpoint inhibitors) have demonstrated evidence of therapeutic activity and are potential bridge to an allogeneic stem-cell transplantation. The review is aimed to present not only salvage strategies; indeed, the paper contains paragraphs about therapy and new treatment options at diagnosis.
Keywords:
Allografting; New salvage treatments; Relapsed/refractory Hodgkin lymphoma.
MeSH terms
-
Antineoplastic Agents, Immunological / administration & dosage
-
Antineoplastic Agents, Immunological / adverse effects
-
Antineoplastic Agents, Immunological / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bleomycin / adverse effects
-
Bleomycin / therapeutic use
-
Brentuximab Vedotin
-
Combined Modality Therapy
-
Dacarbazine / adverse effects
-
Dacarbazine / therapeutic use
-
Doxorubicin / adverse effects
-
Doxorubicin / therapeutic use
-
Drug Resistance, Neoplasm
-
Hodgkin Disease / diagnosis
-
Hodgkin Disease / drug therapy*
-
Hodgkin Disease / immunology
-
Hodgkin Disease / mortality
-
Humans
-
Immunoconjugates / administration & dosage
-
Immunoconjugates / adverse effects
-
Immunoconjugates / therapeutic use*
-
Immunomodulation / drug effects*
-
Molecular Targeted Therapy*
-
Neoplasm Staging
-
Positron-Emission Tomography
-
Retreatment
-
Salvage Therapy
-
Treatment Outcome
-
Vinblastine / adverse effects
-
Vinblastine / therapeutic use
Substances
-
Antineoplastic Agents, Immunological
-
Immunoconjugates
-
Bleomycin
-
Vinblastine
-
Dacarbazine
-
Brentuximab Vedotin
-
Doxorubicin